DANIELE DE PAULA FARIA
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
conferenceObject Radioactive and near-infrared fluorescence in vivo imaging of Non-Hodgkin Lymphoma using 99mTc/Cy7-Fab(Bevacizumab)(2021) CAMACHO, X.; PERRONI, C.; CARNEIRO, C.; JUNQUEIRA, M.; FARIA, D.; GARCIA, M.; FERNANDEZ, M.; BUCHPIGUEL, C.; CERECETTO, H.; CHAMMAS, R.; RIVA, E.; CABRAL, P.; GAMBINI, J.- Radio- and Fluorescent-Labeling of Rituximab Based on the Inverse Electron Demand Diels-Alder Reaction(2021) GARCIA, Maria Fernanda; JUNQUEIRA, Mara de Souza; MORORO, Janio da Silva; CAMACHO, Ximena; FARIA, Daniele de Paula; CARNEIRO, Camila de Godoi; GALLAZZI, Fabio; CHAMMAS, Roger; QUINN, Thomas; CABRAL, Pablo; CERECETTO, HugoThe bioorthogonal reaction between([1,2,4,5])tetrazines with trans-cyclooctene through the inverse electron demand Diels-Alder (IEDDA) has been described as powerful bioconjugation tool. In this work, we explore the IEDDA as a modular conjugation strategy for in vitro and in vivo labeling of Rituximab for the generation of radioactive and fluorescently label immunoconjugates. The strategy allowed the generation, in vitro and in vivo, of conjugated Rituximab with cyanine 5 and 7 and the gamma emmiter technetium-99m.
- 99mTechnetium-or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents(2021) CAMACHO, Ximena; PERRONI, Carolina; MACHADO, Camila L.; CARNEIRO, Camila de Godoi; JUNQUEIRA, Mara de Souza; FARIA, Daniele; GARCIA, Maria F.; FERNANDEZ, Marcelo; ODDONE, Natalia; BENECH, Juan; BUCHPIGUEL, Carlos A.; CERECETTO, Hugo; CHAMMAS, Roger; RIVA, Eloisa; CABRAL, Pablo; GAMBINI, Juan P.Background: Multiple Myeloma (MM) is a malignant hematologic disorder and the second most common blood cancer. Interleukin-6 (IL-6) has been identified as a crucial factor for the proliferation and survival of MM cells and the overexpression of IL-6 receptor is being studied as a molecular target for therapeutic and diagnostic use in myelomas and other comorbidities. Tocilizumab is a humanized monoclonal antibody that binds IL-6R. Objective: We aim to label and evaluate Fab(Tocilizumab) with 99mTechnetium or Cy7 as potential MM imaging agents. Methods: IL-6R distribution was analyzed by Laser Confocal Microscopy (LCM) in MM cell lines. Fab(Tocilizumab) was produced by the digestion of Tocilizumab with papain for 24h at 37 degrees C, derivatized with NHS-HYNIC-Tfa and radiolabeled with Tc-99m. Radiochemical stability and in vitro cell assays were evaluated. Biodistribution and SPECT/CT were performed. Also, Fab(Tocilizumab) was labeled with Cy7 for in vivo fluorescence imaging up to 72h. Results: LCM analysis demonstrates IL-6R distribution on MM cell lines. Incubation with papain resulted in complete digestion of Tocilizumab and exhibited a good purity and homogeneity. Radiolabeling with Tc-99m via NHS-HYNIC-Tfa was found to be fast, easy, reproducible and stable, revealing high radiochemical purity and without interfering with IL-6R recognition. Biodistribution and SPECT/CT studies showed a quick blood clearance and significant kidney and MM engrafted tumor uptake. Cy7-Fab(Tocilizumab) fluorescent imaging allowed MM1S tumor identification up to 72h p.i. Conclusion: These new molecular imaging agents could potentially be used in the clinical setting for staging and follow-up of MM through radioactive whole-body IL-6R expression visualization in vivo. The fluorescent version could be used for tissue sample evaluation and to guide surgical excision, if necessary.
- Synthesis of hydrophilic HYNIC-[1,2,4,5]tetrazine conjugates and their use in antibody pretargeting with Tc-99m(2018) GARCIA, Maria Fernanda; GALLAZZI, Fabio; JUNQUEIRA, Mara de Souza; FERNANDEZ, Marcelo; CAMACHO, Ximena; MORORO, Janio da Silva; FARIA, Daniele; CARNEIRO, Camila de Godoi; COUTO, Marcos; CARRION, Federico; PRITSCH, Otto; CHAMMAS, Roger; QUINN, Thomas; CABRAL, Pablo; CERECETTO, HugoPretargeted imaging, based on the highly reactive process between [1,2,4,5]tetrazines with trans-cyclooctene (TCO), appears as an attractive strategy to overcome disadvantages associated with traditional radioimmunoconjugates. To be successful, the radiolabeled component should react in vivo with the conjugated antibody and the non reactive excess clear fast from the organism. Herein, we explore the in vivo effects of hydrophilic linker incorporation into [1,2,4,5]tetrazine systems bearing a 6-hydrazinonicotinyl (HYNIC) moiety for technetium-99m coordination. Incorporation of a polypeptide chain containing hydrophilic aminoacids, resulted in a derivative with renal clearance. Pretargeted bevacizumab imaging was used as proof of concept.